title: New anticoagulants in atrial fibrillation: an update for clinicians.
abstract: Anticoagulation is vital for stroke and systemic embolism prevention in patients with atrial fibrillation. Current therapy with the vitamin K inhibitor warfarin has many inherent limitations in clinical practice. With the potential of broadening anticoagulation therapy to a larger population, new classes of anticoagulants have recently emerged with the potential for improved efficacy, safety and convenience. Direct thrombin inhibitor and Factor Xa inhibitor classes are showing promise for both patients and clinicians.
authors.forename: Satjit
authors.initials: S
authors.lastname: Bhusri
authors.forename: Jack
authors.initials: J
authors.lastname: Ansell